Yamada Y et al.’s (97) study indicate that in elderly patients (over 75 years of age) with advanced NSCLC and EGFR mutations, EGFR-TKI rechallenge after first-line EGFR-TKI treatment was effective and tolerable. This evidence concerns the gene EGFR and non-small cell lung carcinoma.